CD274 and hepatocellular carcinoma: Both in HCC and RCC chemotherapy is ineffective, antiangiogenic-targeted treatment revolutionized the treatment landscape and combination therapies of either anti-VEGF/ICI or anti-PD-(L)1/CTLA-4 inhibitors have currently become the standard of care for the first-line treatment [20].